RxDoctor Payments Data

Ann Nguyen-Traxler, MD

Internal Medicine · Berkeley, CANPI 1376770933

Payments from drug & device makers

$2,738in general payments, 2019–2025

Across 122 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$556
  • Otsuka America Pharmaceutical, Inc.$478
  • Pfizer$250
  • Amgen$217
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$142
  • Novartis$116
  • plus $979 from 28 others

What the payments were for

  • Food & beverage$2,72199%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,738 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$215,482
Medicare patients
428
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$93,981
Invega SustennaPaliperidone Palmitate21$76,673
XareltoRivaroxaban94$50,935
MounjaroTirzepatide25$26,518
JardianceEmpagliflozin36$26,180
TrulicityDulaglutide20$23,430
OzempicSemaglutide13$20,254
FarxigaDapagliflozin Propanediol30$19,433
JanuviaSitagliptin Phosphate20$18,208
GemtesaVibegron12$11,177
Gabapentin244$10,238
Breo ElliptaFluticasone/Vilanterol21$10,117
MyrbetriqMirabegron12$8,868
Atorvastatin Calcium633$7,959
LokelmaSodium Zirconium Cyclosilicate17$7,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto, Invokana$556$133,581135 claims
PfizerEliquis, Premarin$250$101,739192 claims
Lilly USA, LLCMounjaro, Trulicity$31$49,94845 claims
Boehringer IngelheimJardiance$14$26,18036 claims
Sumitomo Pharma America, Inc.Gemtesa$76$11,17712 claims
Astellas Pharma US IncMyrbetriq$39$8,86812 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$6,904581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →